IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

MT Newswires Live2024-12-30

IDEAYA Biosciences (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for its experimental cancer drug, SHR-4849.

Under the agreement, the drugmaker will develop and commercialize SHR-4849 outside Greater China. Jiangsu Hengrui will be eligible for up to about $1.05 billion in upfront and milestone payments, including a $75 million upfront fee and up to $200 million in development and regulatory milestone payments, as well as commercial success-based milestones.

Hengrui is also eligible to receive mid-single to low-double-digit royalties on sales outside Greater China.

IDEAYA said the upfront and projected research and development costs, including potential milestone payments, will not affect its previously guided cash runway of at least 2028.

The company said the drug candidate has shown "promising" results in preclinical studies, demonstrating tumor regression as a monotherapy and is currently in a phase 1 trial for advanced solid tumors in China.

It added that it intends to file a new drug application for SHR-4849 in the US in H1 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495351502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-30 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495351502","market":"sh","top_or_hot":-1,"title":"IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for its experimental cancer drug, SHR-4849.</p><p>Under the agreement, the drugmaker will develop and commercialize SHR-4849 outside Greater China. Jiangsu Hengrui will be eligible for up to about $1.05 billion in upfront and milestone payments, including a $75 million upfront fee and up to $200 million in development and regulatory milestone payments, as well as commercial success-based milestones.</p><p>Hengrui is also eligible to receive mid-single to low-double-digit royalties on sales outside Greater China.</p><p>IDEAYA said the upfront and projected research and development costs, including potential milestone payments, will not affect its previously guided cash runway of at least 2028.</p><p>The company said the drug candidate has shown \"promising\" results in preclinical studies, demonstrating tumor regression as a monotherapy and is currently in a phase 1 trial for advanced solid tumors in China.</p><p>It added that it intends to file a new drug application for SHR-4849 in the US in H1 2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-30 17:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for its experimental cancer drug, SHR-4849.Under the agreement, the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2495351502","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495351502","pubTimestamp":1735551283,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IDEAYA Biosciences  said Sunday it has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for its experimental cancer drug, SHR-4849.Under the agreement, the drugmaker will develop and commercialize SHR-4849 outside Greater China. Jiangsu Hengrui will be eligible for up to about $1.05 billion in upfront and milestone payments, including a $75 million upfront fee and up to $200 million in development and regulatory milestone payments, as well as commercial success-based milestones.Hengrui is also eligible to receive mid-single to low-double-digit royalties on sales outside Greater China.IDEAYA said the upfront and projected research and development costs, including potential milestone payments, will not affect its previously guided cash runway of at least 2028.The company said the drug candidate has shown \"promising\" results in preclinical studies, demonstrating tumor regression as a monotherapy and is currently in a phase 1 trial for advanced solid tumor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"IDEAYA Biosciences与江苏恒瑞就癌症候选药物SHR-4849签订许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"IDEAYA Biosciences (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for its experimental cancer drug, SHR-4849.Under the agreement, the drugmaker will develop and commercialize SHR-4849 outside Greater China. Jiangsu Hengrui will be eligible for up to about $1.05 billion in upfront and milestone payments, including a $75 million upfront fee and up to $200 million in development and regulatory milestone payments, as well as commercial success-based milestones.Hengrui is also eligible to receive mid-single to low-double-digit royalties on sales outside Greater China.IDEAYA said the upfront and projected research and development costs, including potential milestone payments, will not affect its previously guided cash runway of at least 2028.The company said the drug candidate has shown \"promising\" results in preclinical studies, demonstrating tumor regression as a monotherapy and is currently in a phase 1 trial for advanced solid tumors in China.It added that it intends to file a new drug application for SHR-4849 in the US in H1 2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495351502"}